B
PBE icon

Baird’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Baird’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$399K Sell
7,228
-1,558
-18% -$84.2K ﹤0.01% 1022
2014
Q4 		$441K Sell
8,786
-180
-2% -$8.81K ﹤0.01% 988
2014
Q3 		$414K Buy
8,966
+3,056
+52% +$138K 0.01% 888
2014
Q2 		$258K Buy
+5,910
New +$239K ﹤0.01% 1021
2014
Q1 		– Sell
-5,661
Closed -$210K – 1152
2013
Q4 		$210K Buy
+5,661
New +$203K ﹤0.01% 1056

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
QA
Quantitative Advantage Minnetonka, Minnesota $689M AUM 6.25% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

Baird's PBE Position: Q1 2015 in Review

Baird reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 18% in Q1 2015, selling an estimated $84.2K and leaving 7,228 shares worth $399K. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

Baird first reported a position in PBE in Q4 2013 and has held it in 5 quarters since. The position peaked at $441K in Q4 2014. 87 funds tracked by Wall St. Rank hold PBE as of Q1 2015.

  • Baird held 7,228 shares of Invesco Biotechnology & Genome ETF worth $399K as of Q1 2015.
  • Baird sold 1,558 Invesco Biotechnology & Genome ETF shares in Q1 2015, an estimated $84.2K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Baird's portfolio in Q1 2015, its #1022 holding.
  • Baird first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and has held it in 5 quarters since.
  • Baird's Invesco Biotechnology & Genome ETF position peaked at $441K in Q4 2014.
  • 87 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.